WHAT IS CLAIMED IS:

1. A compound of Formula I:



I

wherein:

R^{1a} and R^{1b} are independently selected from:

1) hydrogen,
2) unsubstituted or substituted C_1-C_{10} alkyl,
3) OR^3,
4) $N(R^3)_2$,
5) unsubstituted or substituted aryl,
6) unsubstituted or substituted heterocycle, and
7) unsubstituted or substituted C_3-C_{10} cycloalkyl;

R^{1c} is independently selected from:

1) hydrogen,
2) C_1-C_{10} alkyl,
3) OR^3,
4) $N(R^3)_2$,
5) C_3-C_{10} cycloalkyl,
6) aryl, and
7) heterocycle;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7;

R^2 is independently selected from:

1) hydrogen,
2) unsubstituted or substituted C_1-C_{10} alkyl,
3) $N(R^3)_2$,
4) OR^3,
5) unsubstituted or substituted aryl, and
6) unsubstituted or substituted C_3-C_{10} cycloalkyl;

R^3 is independently selected from:

1) hydrogen,
2) C_1-C_{10} alkyl,
3) aryl,
4) heterocycle,
5) C_3-C_{10} cycloalkyl,
6) CF_3,
7) C_2-C_6 alkenyl,
8) C_2-C_6 alkynyl,
9) $S(O)_mR^6$, and
10) $C(O)R^6$;

said alkyl, cycloalkyl, aryl, heterocycle, alkynyl, and alkenyl is optionally substituted with at least one substituent selected from R^7;

R^5 is independently selected from:

1) hydrogen,
2) halogen,
3) $-(CR^{1c}{}_2)_nOR^3$,
4) $-(CR^{1c}{}_2)_nR^6$,
5) $-C(O)OR^3$,
6) $-C(O)R^3$,
7) $-C{\equiv}CR^3$,
8) $-R^3C{=}C(R^3)_2$,
9) $-OS(O)_mR^6$,
10) $-NO_2$,
11) $-(CR^{1c}{}_2)_nN(R^3)_2$,

12) $-N(R^3)C(O)R^3$,
13) $-N(R^3)S(O)_mR^6$,
14) $-(CR^{1c}{}_2)_nNR^3(CR^{1c}{}_2)_nC(O)NR^3{}_2$,
15) $-O(CR^{1c}{}_2)_nC(O)N(R^3)_2$,
16) $-O(CR^{1c}{}_2)_nC(O)OR^3$,
17) $-NR^3(CR^{1c}{}_2)_nN(R^3)_2$,
18) $-(CR^{1c}{}_2)_nNR^3R^6OR^3$,
19) $-S(O)_mR^6$,
20) $-S(O)_mN(R^3)_2$,
21) -CN,
22) $-(CR^{1c}{}_2)_nN(R^3)(CR^{1c}{}_2)_nR^6$, and
23) $-(CR^{1c}{}_2)_nC(O)N(R^3)_2$;

R^6 is independently selected from:

1) C_1-C_{10} alkyl,
2) C_3-C_{10} cycloalkyl,
3) aryl, and
4) heterocycle;

said, alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7;

R^7 is independently selected from:

1) hydrogen,
2) unsubstituted or substituted C_1-C_{10} alkyl,
3) unsubstituted or substituted C_3-C_{10} cycloalkyl,
4) unsubstituted or substituted aryl,
5) halogen,
6) OR^3,
7) CF_3,
8) unsubstituted or substituted heterocycle,
9) $S(O)_mN(R^3)_2$,
10) $C(O)OR^3$,
11) $C(O)R^3$,
12) CN,

13) $C(O)N(R^3)_2$,
14) $N(R^3)C(O)R^3$,
15) $S(O)_mR^6$, and
16) NO_2;

Y and Z are independently selected from:

1) hydrogen,
2) R^6,
3) OR^3,
4) $N(R^3)_2$,
5) $C(O)OR^3$,
6) $C(O)N(R^3)_2$,
7) $C(O)R^3$,
8) halogen,
9) $N(R^3)(CR^{1c}_2)_nC(O)N(R^3)_2$,
10) $S(O)_mN(R^3)_2$,
11) $N(R^3)C(O)OR^3$,
12) $N(R^3)S(O)_mR^6$,
13) $N(R^3)C(O)R^3$,
14) $N(R^3)(CR^{1c}_2)_nR^3$,
15) $S(O)_mR^6$,
16) $R^6S(O)_mN(R^3)_2$,
17) $R^6S(O)_mR^6$,
18) $N(R^3)\ S(O)_m\ (CR^{1c}_2)_nR^6$,
19) $N(R^3)S(O)_mR^6OR^3$,
20) $N(R^3)C(O)N(R^3)_2$,
21) $N(R^3)C(O)R^6OR^3$,
22) $N(R^3)(CR^{1c}_2)_nR^6OR^3$,
23) $N(R^3)OR^3$, and
24) $N(R^3)S(O)_mR^6NO_2$;

m is independently 0, 1 or 2;

n is independently 0 to 6;

s is 0 to 6;

t is 0 to 6;
w is 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to Claim 1,

wherein:

R^{1a} and R^{1b} are independently selected from:

1) hydrogen,
2) unsubstituted or substituted C_1-C_{10} alkyl,
3) unsubstituted or substituted aryl,
4) unsubstituted or substituted heterocycle, and
5) OR^3;

R^{1c} is independently selected from:

1) hydrogen,
2) C_1-C_{10} alkyl,
3) OR^3,
4) $N(R^3)_2$,
5) aryl, and
6) heterocycle;

said alkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7;

R^2 is:

1) H,
2) unsubstituted or substituted alkyl,
3) OR^3, or
4) $N(R^3)_2$;

R^3 is independently selected from:

1) hydrogen,
2) C_1-C_{10} alkyl,
3) aryl,

4) heterocycle,
5) C_3-C_{10} cycloalkyl,
6) CF_3,
7) $S(O)_mR^6$, and
8) $C(O)R^6$;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R^7;

R^5 is independently selected from:

1) hydrogen,
2) halogen,
3) $-OR^3$,
4) $-C(O)OR^3$,
5) $-C(O)R^3$,
6) $-C{\equiv}CR^3$,
7) $-R^3C{=}C(R^3)_2$,
8) $-OS(O)_mR^6$,
9) $-NO_2$,
10) $-N(R^3)_2$,
11) $-N(R^3)C(O)R^3$,
12) $-N(R^3)S(O)_mR^6$,
13) $-(CR^{1c}_2)_nNR^3(CR^{1c}_2)_nC(O)NR^3_2$,
14) $-O(CR^{1c}_2)_nC(O)N(R^3)_2$,
15) $-O(CR^{1c}_2)_nC(O)OR^3$,
16) $-NR^3(CR^{1c}_2)_nN(R^3)_2$,
17) $-(CR^{1c}_2)_nNR^3R^6OR^3$,
18) $-S(O)_mR^6$,
19) $-S(O)_mN(R^3)_2$,
20) -CN, and
21) $-(CR^{1c}_2)_nN(R^3)(CR^{1c}_2)_nR^6$;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to Claim 2,

wherein:

R^{1a} and R^{1b} are independently selected from hydrogen, unsubstituted or substituted C_1-C_{10} alkyl, OR^3, and unsubstituted or substituted aryl;

R^{1c} is independently selected from:

1) hydrogen,
2) C_1-C_{10} alkyl,
3) OR^3, and
4) aryl;

said alkyl and aryl is optionally substituted with at least one substituent selected from R^7;

R^2 is:

1) OR^3, or
2) $N(R^3)_2$;

R^5 is independently selected from:

1) hydrogen,
2) $(CR^{1c}{}_2)_nR^6$,
3) halogen,
4) $-(CR^{1c}{}_2)_nOR^3$,
5) $-C(O)OR^3$,
6) $-C(O)R^3$,
7) $-C{\equiv}CR^3$,
8) $-R^3C{=}C(R^3)_2$,
9) $(CR^{1c}{}_2)_nC(O)N(R^3)_2$, and
10) $(CR^{1c}{}_2)_nN(R^3)_2$;

Y is:

1) hydrogen,
2) R^6,
3) OR^3,
4) $C(O)R^3$,

5) $C(O)N(R^3)_2$, or
6) $N(R^3)_2$;

Z is:

1) hydrogen,
2) R^6,
3) OR^3,
4) $N(R^3)_2$,
5) $C(O)OR^3$,
6) $C(O)N(R^3)_2$,
7) $C(O)R^3$,
8) halogen,
9) $N(R^3)(CR^{1c}_2)_nC(O)N(R^3)_2$,
10) $S(O)_mN(R^3)_2$,
11) $N(R^3)C(O)OR^3$,
12) $N(R^3)S(O)_mR^6$,
13) $N(R^3)C(O)R^3$,
14) $N(R^3)(CR^{1c}_2)_nR^3$, or
15) $S(O)_mR^6$;

n is independently 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A compound selected from:

5-Chloro-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;

3-(Aminosulfonyl)-5-chloro-1*H*-indole-2-carboxamide;

5-Bromo-3-({methyl[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3 yl)methyl] amino} sulfonyl)-1H-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-iodo-1*H*-indole-2-carboxamide;

3-[(Dimethylamino)sulfonyl]-5-methoxy-1H-indole-2-carboxamide;

5-Chloro-3-{[(2-phenethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-[(benzylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(cyclohexylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(1-naphthylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(3-phenylpropyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-[(ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(propylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(butylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(pentylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-[(diethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(*iso*-propylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(cyclobutylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(cyclopentylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(4-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(3-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-chlorophenyl)amino}sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(4-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(3-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-chlorophenyl)methylamino}sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(*tert*-butylamino)sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-[(pyrrolidin-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(piperidin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(1-methyl-1*H*-benzimidazol-2-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-[(benzamideamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(5-aminotetrazole)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(pyridin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-[(pyridin-2-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-methyoxyethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-[(dimethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-chloro-1*H*-indole-2-carboxamide ;

5-Chloro-3-{[(2-hydroxyethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-morpholin-4-ylethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-methoxyethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[({[2-(2-acetamide)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

N-{[2-(Aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl}-*N*-methyl-β-alaninamide;

5-Bromo-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;

Ethyl *N*-{[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl} *N*-methyl-β-alaninate;

5-Bromo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

(±)-5-Bromo-3-{[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({methyl[2-(1*H*-1,2,4-triazol-1-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-{[methyl(tetrahydro-2*H*-pyran-4-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

3-({[4-(Aminosulfonyl)benzyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

5-Chloro-3-{[*iso*-propyl(2-methoxyethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-hydroxy-1*H*-indole-2-carboxamide;

3-{[(2-Bromoethyl)(2-hydroxyethyl)amino]sulfonyl}-5-methoxy-1*H*-indole-2-carboxamide;

5-Chloro-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{[(2,3-dihydroxypropyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-{[(2-hydroxyethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

N-{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-*N*-methylglycine;

N-{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-*N*-methylglycinamide;

5-Bromo-3-({[4-(methylsulfonyl)benzyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

3-[({2-[4-(Aminosulfonyl)phenyl]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

3-{[(5-Amino-5-oxopentyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

tert-Butyl 2-({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl}amino)-ethylcarbamate;

3-{[(2-Aminoethyl)amino]sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-[({ethylsulfonylamino}ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1 *H*-indole-2-carboxamide;

5-Bromo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Fluoro-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({[2-({[(4-methoxyphenyl)amino]carbonyl}amino)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[({3-[(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3-[({3-[(4-chlorophenyl)sulfonyl]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3-[({propylsulfonylamino}ethylamino)sulfonyl]-1*H*-indole-2-carboxamide hydrochloride;

5-Bromo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide ;

5-Bromo-3-[({2-[(phenylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[({2-[(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

3-[({2-[(Benzylsulfonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(3-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(2,5-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H* -indole-2-carboxamide;

5-Bromo-3-{[(2-{[(5-bromo-2-methoxyphenyl)sulfonyl]amino}ethyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({[2-({[2-(trifluoromethoxy)phenyl]sulfonyl}amino)ethyl]amino} sulfonyl)-1 *H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(2-methoxy-5-methylphenyl)sulfonyl]amino}ethyl)amino] sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-cyanophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(3,4-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[({3-[(phenylsulfonyl)amino]propyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(3-{[(4-methoxyphenyl)sulfonyl]amino}propyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

3-[({3-[(Benzylsulfonyl)amino]propyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

3-[({2-[(Aminocarbonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(4-bromophenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[({2-[(thien-3-ylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(3-chlorobenzyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{[(2-{[(2-phenylethyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxybenzoyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxybenzyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[({2-[(4-methoxyphenyl)(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

3-[({2-[Acetyl(4-methoxyphenyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Iodo-3-{[cyclopropyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Iodo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-{[methoxy(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Iodo-3-{[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Iodo-3-{[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1-*H*-indole-2-carboxamide;

5-chloro-3-{[methyl(tetrahydro-2H-pyran-4-yl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-chloro-3-({[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-[(tetrahydro-2H-pyran-4-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-chloro-3-{[(1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-chloro-3-({[(3-methyloxetan-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-[(tetrahydrofuran-3-ylamino)sulfonyl]-1H-indole-2-carboxamide;

5-chloro-3-({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({[2-(2-methoxyphenyl)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[3-(trifluoromethyl)benzyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-chloro-3-({[2-(2,3-dihydro-1*H*-indol-1-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-({methyl[(1-methylpiperidin-3-yl)methyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-{[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl) amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(3-ethoxypropyl) amino]sulfonyl}-1H-indole-2-carboxamide;

3-[({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino) methyl]-1-benzylpyrrolidine;

5-bromo3-({[(1-benzylpyrrolidin-3-yl)methyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-bromo-3-{[(3-pyridin-3-ylpropyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

1-[2-({[2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl}amino)ethyl]-4-phenylpiperidine;

5-bromo-3-{[(3-cyclohexylpropyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(4,4-diphenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(3-butoxypropyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-({[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino} sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-({[4-(4-tert-butoxyphenyl)butyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{[(2-methoxy-1-methylethyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{[(4-phenylbutyl)amino]sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-[({2-[(2,6-dichlorobenzyl)thio]ethyl}amino) sulfonyl]-1H-indole-2-carboxamide;

5-bromo-3-({[2-(tert-butylthio)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-[({6-[(4-chlorobenzyl)amino]-6-oxohexyl}amino)sulfonyl]-1H-indole-2-carboxamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. The compound according to Claim 4, that is selected from:

5-Chloro-3-{[ethyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide



;

(±)-5-Bromo-3-{[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide



;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide



;

5-Bromo-3-{[(2-{[(4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide



;

5-bromo-3-{[(3-butoxypropyl)amino]sulfonyl}-1H-indole-2-carboxamide



;

5-bromo-3-({[3-(4-tert-butoxyphenyl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide



;

5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide



;

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier..

7. A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

8. The method of Claim 7 wherein the protein kinase is an RTK.

9. The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.

10. A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

11. A method of Claim 10, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

1) cancer,
2) diabetes,
3) an autoimmune disorder,
4) a hyperproliferation disorder,

5) aging,
6) acromegaly, and
7) Crohn's disease.

12. A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

14. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) an angiogenesis inhibitor.

15. The method of Claim 14, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

16. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

17. The method of Claim 16 wherein radiation therapy is also administered.

18. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

19. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

20. The method of Claim 19 wherein the GPIIb/IIIa antagonist is tirofiban.

21. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.

22. A process for preparing an alkyl 5-iodo-1*H*-indole-2-carboxylate which comprises the steps of:

a) combining alkyl 1*H*-indole-2-carboxylate, iodine, sodium periodate and sulfuric acid in an alcohol, and heating to a temperature of about 50 °C to about 100 °C to obtain a product;
b) adding the product to a solution of organic solvent and aqueous solution to create a first biphasic mixture;
c) removing, drying, filtering and concentrating the organic layer;
d) dissolving the organic layer in an alcohol;
e) adding zinc and aqueous acid to produce a mixture;
f) combining the mixture with water to create a second biphasic mixture; and
g) extracting, drying and filtering the organic layer of the second biphasic mixture to obtain the alkyl 5-iodo-1*H*-indole-2-carboxylate.

23. The process of Claim 22 wherein the alkyl 5-iodo-1*H*-indole-2-carboxylate is ethyl 5-iodo-1*H*-indole-2-carboxylate.